A Borderline ECG Reading Predicted Later AFib in One Trial
People whose single-lead ECG read 'possible AFib' or an unclear 'other' result, not a clean diagnosis, still had a higher chance of an AFib diagnosis later.
Evidence rating for the proposition “Consumer wearable photoplethysmography detects atrial fibrillation accurately enough for screening”: Established
In one large trial, yes, it can mean something. The VITAL-AF randomized trial tested whether an automated single-lead ECG reading carries prognostic value for future AFib, even when the reading itself doesn't produce an immediate diagnosis. Among more than 30,000 participants without existing AFib, those classified as 'possible AFib' at screening had nearly two and a half times the risk of a later AFib diagnosis compared with those classified as normal. The broader 'other' category, readings that were neither clearly normal nor clearly possible AFib, also carried elevated risk.
Does a borderline single-lead ECG reading mean anything for future risk?
Most consumer conversation about wearable ECG accuracy is about point-in-time detection: does the device correctly flag AFib while it's actually happening. VITAL-AF asked something different and, in a specific way, more forward-looking: if a single-lead ECG reading doesn't show AFib right now, does the pattern of that reading still say anything about the person's risk of developing AFib later.
That's a meaningfully different use case. A device could be excellent at catching AFib in the moment and still say nothing useful about future risk in someone whose current reading looks unremarkable, or it could do both. VITAL-AF was designed specifically to test the second, prognostic question.
1 study
- In the VITAL-AF trial, over 30,000 participants without prevalent AFib were grouped by automated single-lead ECG classification (never screened, normal, other, or possible AFib). The 'possible AFib' group had the highest AFib incidence (5.91 per 100 person-years) and nearly 2.5 times the adjusted hazard of incident AFib compared with the normal group (adjusted hazard ratio 2.48). The broader 'other' classification also carried elevated hazard compared with normal (adjusted hazard ratio 1.41).
How this differs from AI risk-scoring on a normal-looking reading
The site's existing coverage of whether AI can detect hidden AFib risk from a normal ECG addresses a related but distinct question: can a machine-learning model trained to spot subtle patterns in an ECG that reads as normal to a cardiologist still flag elevated future risk. VITAL-AF is testing something more specific and mechanistically different: the trial's own automated single-lead classification system's built-in categories, including an explicit 'possible AFib' presumptive-positive category and a separate, broader 'other' (non-normal, non-possible-AFib) category, and whether those categories carry real incident-AFib signal in a large, prospective, randomized dataset.
The two findings are complementary rather than redundant. One is about AI pattern recognition in normal-appearing readings specifically. This one is about a trial's real-world screening categories, including readings that already look presumptively abnormal (possible AFib) but don't meet the bar for an immediate diagnosis, and what happens to those people over the following months and years.
This finding is about screening categories from automated 1-lead ECG interpretation used in a specific clinical trial protocol, not a claim that every consumer smartwatch's own AFib alert algorithm produces directly comparable risk categories. The trial's classification system is the specific tool being validated here.
Why this matters for how a non-diagnostic reading gets treated
The practical implication is that a single-lead ECG screening program built around this classification system has a real basis for treating 'possible AFib' and even the broader 'other' category as more than a false alarm to dismiss, since both carried statistically real, adjusted elevated hazard for a future AFib diagnosis in this trial. That's a useful piece of information for how a screening program, or an individual reading their own device's classification, should weight a non-diagnostic but non-normal result.
This is a distinct question from whether catching AFib earlier, through any method, actually changes stroke outcomes, which is covered in the site's existing coverage of major AFib-screening outcome trials. VITAL-AF's contribution here is specifically about risk stratification and prognosis, not about downstream clinical benefit from acting on that risk information.
Common questions
Does a normal single-lead ECG reading mean no AFib risk?
This trial specifically studied people whose reading wasn't classified as normal but also wasn't diagnostic of AFib. Those 'possible AFib' and broader 'other' categories carried real elevated future risk. The trial doesn't directly address risk for the 'normal' classification group beyond serving as the comparison baseline.
How much higher was the future AFib risk for the 'possible AFib' group?
Nearly 2.5 times higher (adjusted hazard ratio 2.48) compared with the normal classification group, with the highest incidence rate of any group studied.
Is this the same as AI detecting hidden risk in a normal-looking ECG?
No, though related. That coverage is about machine-learning pattern detection in readings that look normal to a cardiologist. This trial is about a screening program's own built-in classification categories, including explicitly non-normal but non-diagnostic readings, and their prognostic value in a large randomized trial.
Does this mean earlier detection through this method prevents strokes?
This trial's finding is about risk prediction, not about downstream clinical outcomes. Whether earlier AFib detection through any screening method changes stroke risk is a separate question this trial did not address.